{
  "Disease activity (follow up: 3 months; assessed with: ACR 20)": {
    "No of studies": [
      "1"
    ],
    "Study design": "randomised trials",
    "Risk of bias": [
      "very serious",
      "a"
    ],
    "Inconsistency": "not serious",
    "Indirectness": [
      "serious",
      "b"
    ],
    "Imprecision": [
      "very serious",
      "c"
    ],
    "Other considerations": "none",
    "No of patients": {
      "IA corticosteroids alone": "25/25 (100.0%)",
      "Add/Switch DMARD(s)": "21/25 (84.0%)"
    },
    "Effect": {
      "Relative (95% CI)": "RR 1.19 (0.99 to 1.43)",
      "Absolute (95% CI)": "160 more per 1,000 (from 8 fewer to 361 more)"
    },
    "Certainty": " VERY LOW",
    "Importance": "CRITICAL"
  },
  "Disease activity (follow up: 3 months; assessed with: ACR 50)": {
    "No of studies": [
      "1"
    ],
    "Study design": "randomised trials",
    "Risk of bias": [
      "serious",
      "a"
    ],
    "Inconsistency": "not serious",
    "Indirectness": [
      "serious",
      "b"
    ],
    "Imprecision": [
      "serious",
      "d"
    ],
    "Other considerations": "none",
    "No of patients": {
      "IA corticosteroids alone": "15/25 (60.0%)",
      "Add/Switch DMARD(s)": "5/25 (20.0%)"
    },
    "Effect": {
      "Relative (95% CI)": "RR 3.00 (1.29 to 7.00)",
      "Absolute (95% CI)": "400 more per 1,000 (from 58 more to 1,000 more)"
    },
    "Certainty": " VERY LOW",
    "Importance": "CRITICAL"
  },
  "Disease activity (follow up: 3 months; assessed with: ACR 70)": {
    "No of studies": [
      "1"
    ],
    "Study design": "randomised trials",
    "Risk of bias": [
      "very serious",
      "a"
    ],
    "Inconsistency": "not serious",
    "Indirectness": [
      "serious",
      "b"
    ],
    "Imprecision": [
      "very serious",
      "e"
    ],
    "Other considerations": "none",
    "No of patients": {
      "IA corticosteroids alone": "9/25 (36.0%)",
      "Add/Switch DMARD(s)": "0/25 (0.0%)"
    },
    "Effect": {
      "Relative (95% CI)": "RR 19.00 (1.17 to 309.77)",
      "Absolute (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)"
    },
    "Certainty": " VERY LOW",
    "Importance": "CRITICAL"
  },
  "Disease activity (follow up: 3 months; assessed with: DAS28-ESR)": {
    "No of studies": [
      "1"
    ],
    "Study design": "randomised trials",
    "Risk of bias": [
      "very serious",
      "a"
    ],
    "Inconsistency": "not serious",
    "Indirectness": [
      "serious",
      "b"
    ],
    "Imprecision": [
      "very serious",
      "f"
    ],
    "Other considerations": "none",
    "No of patients": {
      "IA corticosteroids alone": "25",
      "Add/Switch DMARD(s)": "25"
    },
    "Effect": {
      "Relative (95% CI)": "-",
      "Absolute (95% CI)": "MD 1.6 lower (2.21 lower to 0.99 lower)"
    },
    "Certainty": " VERY LOW",
    "Importance": "CRITICAL"
  },
  "Disability (follow up: 3 months; assessed with: HAQ-DI)": {
    "No of studies": [
      "1"
    ],
    "Study design": "randomised trials",
    "Risk of bias": [
      "very serious",
      "a"
    ],
    "Inconsistency": "not serious",
    "Indirectness": [
      "serious",
      "b"
    ],
    "Imprecision": [
      "very serious",
      "f"
    ],
    "Other considerations": "none",
    "No of patients": {
      "IA corticosteroids alone": "25",
      "Add/Switch DMARD(s)": "25"
    },
    "Effect": {
      "Relative (95% CI)": "-",
      "Absolute (95% CI)": "MD 0.24 lower (0.42 lower to 0.06 lower)"
    },
    "Certainty": " VERY LOW",
    "Importance": "IMPORTANT"
  }
}